Atea Pharmaceuticals Analyst Ratings
Atea Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/27/2023 | 31.29% | SVB Leerink | $8 → $6 | Maintains | Market Perform |
| 01/24/2023 | -12.47% | Morgan Stanley | $7 → $4 | Maintains | Underweight |
| 08/15/2022 | 53.17% | Morgan Stanley | $6 → $7 | Maintains | Underweight |
| 03/02/2022 | 75.05% | JP Morgan | $10 → $8 | Maintains | Neutral |
| 03/01/2022 | 96.94% | SVB Leerink | $10 → $9 | Maintains | Market Perform |
| 02/16/2022 | 118.82% | SVB Leerink | $11 → $10 | Maintains | Market Perform |
| 01/06/2022 | 53.17% | Morgan Stanley | $14 → $7 | Downgrades | Equal-Weight → Underweight |
| 11/18/2021 | 140.7% | SVB Leerink | → $11 | Downgrades | Outperform → Market Perform |
| 10/20/2021 | 337.64% | SVB Leerink | $60 → $20 | Maintains | Outperform |
| 10/20/2021 | 250.11% | JP Morgan | $61 → $16 | Downgrades | Overweight → Neutral |
| 10/05/2021 | 1103.5% | Morgan Stanley | → $55 | Downgrades | Overweight → Equal-Weight |
| 09/09/2021 | 1212.91% | SVB Leerink | → $60 | Initiates Coverage On | → Outperform |
| 08/18/2021 | 709.63% | Morgan Stanley | $35 → $37 | Maintains | Overweight |
| 06/03/2021 | 665.86% | Morgan Stanley | $82 → $35 | Maintains | Overweight |
| 04/06/2021 | 1694.31% | Morgan Stanley | $49 → $82 | Maintains | Overweight |
| 01/29/2021 | 1344.2% | JP Morgan | $45 → $66 | Maintains | Overweight |
| 11/25/2020 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 884.68% | JP Morgan | → $45 | Initiates Coverage On | → Overweight |
| 11/24/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 972.21% | Morgan Stanley | → $49 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年1月27日 | 31.29% | SVB Leerink | $8→$6 | 維護 | 市場表現 |
| 01/24/2023 | -12.47% | 摩根士丹利 | $7→$4 | 維護 | 體重不足 |
| 2022年08月15日 | 53.17% | 摩根士丹利 | $6→$7 | 維護 | 體重不足 |
| 03/02/2022 | 75.05% | 摩根大通 | $10→$8 | 維護 | 中性 |
| 03/01/2022 | 96.94% | SVB Leerink | $10→$9 | 維護 | 市場表現 |
| 02/16/2022 | 118.82% | SVB Leerink | $11→$10 | 維護 | 市場表現 |
| 01/06/2022 | 53.17% | 摩根士丹利 | $14→$7 | 評級下調 | 等重→減碼 |
| 2021年11月18日 | 140.7% | SVB Leerink | →$11 | 評級下調 | 跑贏→市場表現 |
| 10/20/2021 | 337.64% | SVB Leerink | $60→$20 | 維護 | 跑贏大盤 |
| 10/20/2021 | 250.11% | 摩根大通 | $61→$16 | 評級下調 | 超重→中性 |
| 10/05/2021 | 1103.5% | 摩根士丹利 | →$55 | 評級下調 | 超重→等重 |
| 09/09/2021 | 1212.91% | SVB Leerink | →$60 | 開始承保 | →跑贏大盤 |
| 2021/08/18 | 709.63% | 摩根士丹利 | $35→$37 | 維護 | 超重 |
| 06/03/2021 | 665.86% | 摩根士丹利 | $82→$35 | 維護 | 超重 |
| 04/06/2021 | 1694.31% | 摩根士丹利 | $49→$82 | 維護 | 超重 |
| 2021/01/29 | 1344.2% | 摩根大通 | $45→$66 | 維護 | 超重 |
| 11/25/2020 | - | Evercore ISI集團 | 開始承保 | →跑贏大盤 | |
| 11/24/2020 | 884.68% | 摩根大通 | →$45 | 開始承保 | →超重 |
| 11/24/2020 | - | 威廉·布萊爾 | 開始承保 | →跑贏大盤 | |
| 11/24/2020 | 972.21% | 摩根士丹利 | →$49 | 開始承保 | →超重 |
What is the target price for Atea Pharmaceuticals (AVIR)?
ATEA製藥(Avir)的目標價是多少？
The latest price target for Atea Pharmaceuticals (NASDAQ: AVIR) was reported by SVB Leerink on January 27, 2023. The analyst firm set a price target for $6.00 expecting AVIR to rise to within 12 months (a possible 31.29% upside). 6 analyst firms have reported ratings in the last year.
ATEA製藥(納斯達克：AVIR)的最新目標價是由SVB Leerink於2023年1月27日報道的。這家分析公司將目標價定為6.00美元，預計Avir將在12個月內上漲(可能上漲31.29%)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Atea Pharmaceuticals (AVIR)?
分析師對安泰製藥(AVIR)的最新評級是多少？
The latest analyst rating for Atea Pharmaceuticals (NASDAQ: AVIR) was provided by SVB Leerink, and Atea Pharmaceuticals maintained their market perform rating.
ATEA製藥(納斯達克代碼：AVIR)的最新分析師評級由SVB Leerink提供，ATEA製藥維持其市場表現評級。
When is the next analyst rating going to be posted or updated for Atea Pharmaceuticals (AVIR)?
安泰製藥(Avir)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atea Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atea Pharmaceuticals was filed on January 27, 2023 so you should expect the next rating to be made available sometime around January 27, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與ATEA製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。對ATEA製藥的上一次評級是在2023年1月27日提交的，所以你應該預計下一次評級將在2024年1月27日左右的某個時候公佈。
Is the Analyst Rating Atea Pharmaceuticals (AVIR) correct?
分析師對安泰製藥(AVIR)的評級正確嗎？
While ratings are subjective and will change, the latest Atea Pharmaceuticals (AVIR) rating was a maintained with a price target of $8.00 to $6.00. The current price Atea Pharmaceuticals (AVIR) is trading at is $4.57, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的ATEA製藥(Avir)評級維持不變，目標價在8.00美元至6.00美元之間。ATEA製藥(Avir)目前的交易價格為4.57美元，超出了分析師的預測區間。